Olema Pharmaceuticals logo

Olema PharmaceuticalsNASDAQ: OLMA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

19 November 2020

Next earnings report:

11 March 2025

Last dividends:

N/A

Next dividends:

N/A
$503.07 M
-47%vs. 3y high
66%vs. sector
-vs. 3y high
-vs. sector
-44%vs. 3y high
63%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 106 min ago
$8.78+$0.80(+10.03%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

OLMA Latest News

Olema Oncology to Participate in Upcoming Investor Conferences
globenewswire.com06 November 2024 Sentiment: POSITIVE

SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that its management team will participate in the following upcoming investor conferences:

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
globenewswire.com23 October 2024 Sentiment: POSITIVE

SAN FRANCISCO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced results from three preclinical studies that will be presented during poster sessions at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) in Barcelona, Spain.

Olema Oncology to Participate in Upcoming Investor Conferences in June
globenewswire.com28 May 2024 Sentiment: POSITIVE

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that its management team will participate in the following upcoming investor conferences:

Olema Oncology to Participate in Upcoming Investor Conferences in May
GlobeNewsWire01 May 2024 Sentiment: POSITIVE

Olema Pharmaceuticals, Inc. ("Olema", "Olema Oncology", Nasdaq: OLMA), a company developing targeted therapies for women's cancers, shared that its management team will be present at upcoming investor conferences.

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
GlobeNewsWire08 April 2024 Sentiment: POSITIVE

SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on “Breast Cancer – Shifting an Entrenched Paradigm” at the 2024 CG Horizons in Oncology Virtual Conference on Monday, April 15, 2024, at 2:00 p.m. ET.

Olema Oncology to Participate in Upcoming Investor Conferences
GlobeNewsWire06 February 2024 Sentiment: POSITIVE

SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company will participate in the following upcoming investor conferences:

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
GlobeNewsWire28 November 2023 Sentiment: POSITIVE

Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on Dec. 7, 2023

Olema Pharmaceuticals: Advancing On Multiple Fronts
Seeking Alpha28 November 2023 Sentiment: POSITIVE

Today, we revisit Olema Pharmaceuticals, Inc. for the first time in two years. Olema is a clinical-stage biotech company focused on developing therapies for women's cancers. Their primary product candidate, palazestrant, has been granted FDA Fast Track designation for the treatment of metastatic breast cancer. Palazestrant is advancing in development both as a potential monotherapy and as part of potential combination therapies.

Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
Zacks Investment Research27 November 2023 Sentiment: POSITIVE

Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.

Olema Oncology to Participate in Upcoming Investor Conferences in November
GlobeNewsWire01 November 2023 Sentiment: POSITIVE

SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company will present at the following upcoming investor conferences in November:

What type of business is Olema Pharmaceuticals?

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

What sector is Olema Pharmaceuticals in?

Olema Pharmaceuticals is in the Healthcare sector

What industry is Olema Pharmaceuticals in?

Olema Pharmaceuticals is in the Biotechnology industry

What country is Olema Pharmaceuticals from?

Olema Pharmaceuticals is headquartered in United States

When did Olema Pharmaceuticals go public?

Olema Pharmaceuticals initial public offering (IPO) was on 19 November 2020

What is Olema Pharmaceuticals website?

https://olema.com

Is Olema Pharmaceuticals in the S&P 500?

No, Olema Pharmaceuticals is not included in the S&P 500 index

Is Olema Pharmaceuticals in the NASDAQ 100?

No, Olema Pharmaceuticals is not included in the NASDAQ 100 index

Is Olema Pharmaceuticals in the Dow Jones?

No, Olema Pharmaceuticals is not included in the Dow Jones index

When was Olema Pharmaceuticals the previous earnings report?

No data

When does Olema Pharmaceuticals earnings report?

The next expected earnings date for Olema Pharmaceuticals is 11 March 2025